Previous 10 | Next 10 |
Syros Pharmaceuticals (NASDAQ: SYRS ) has priced its public offerings of (i) 8,667,333 common shares and Class A warrants to purchase up to 1,951,844 common shares, at $7.50 per common share and warrant and (ii) 666 shares of Series A convertible preferred stock, convertible into 666,000 c...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has priced its concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to...
Syros Pharmaceuticals (NASDAQ: SYRS ) launches two concurrent equity offerings, one comprised of stock and Class A warrants and the other Series A convertible preferred stock and Class A warrants. More news on: Syros Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it is offering to sell, subject to market and other conditions, (i) shares of its common stock and Class A warrants to purchase common stock, and (ii) sha...
Presentations Highlight Syros’ Leadership in Selective CDK7 Inhibition as Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers Alterations in RB Pathway Predictive of Response to SY-1365 in Ovarian Cancer Models, Supporting Further Evaluation as Potentia...
The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with this Read more ...
Syros Pharmaceuticals (SYRS) Q4 2018 Earnings Conference Call March 7, 2019 08:30 AM ET Company Participants Naomi Aoki - VP, Corporate Communications and IR Dr. Nancy Simonian - CEO Dr. David Roth - Chief Medical Officer Joe Ferra - CFO Conference Call Participants Phi...
Syros Pharmaceuticals (NASDAQ: SYRS ): Q4 GAAP EPS of -$0.54 misses by $0.03 . More news on: Syros Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Expects to Report Updated Data on SY-1425 in Combination with Azacitidine in Newly Diagnosed Unfit AML Patients in Second Half of 2019 Expects to Report Initial Data from Expansion Portion of Phase 1 Trial of SY-1365 in Fourth Quarter of 2019 Announces Plans to Expand Ongoing Phas...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences. Cowen and Company 39 th Annual Health Care Conference in Boston on Wednesday, March 13, 2...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...